Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Fulcrum Therapeutics ( (FULC) ) just unveiled an update.
Fulcrum Therapeutics has released an updated corporate presentation outlining its advancements in developing Pociredir, a promising oral small molecule for sickle cell disease. With a cash position of approximately $240 million and projected financial runway into 2027, Fulcrum is strategically positioned to potentially transform the treatment landscape for SCD, aiming for Phase 1b clinical data disclosures by the end of 2025, reflecting its commitment to addressing significant unmet needs in rare diseases.
More about Fulcrum Therapeutics
Fulcrum Therapeutics operates in the biotechnology industry, focusing on the development of small molecule therapies aimed at modifying gene expression in genetically defined rare diseases. Their primary product candidate, Pociredir, targets sickle cell disease (SCD) by inducing fetal hemoglobin (HbF), with a strategic focus on benign hematology and a robust pipeline for sustainability.
YTD Price Performance: -9.71%
Average Trading Volume: 894,769
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $235.7M
Find detailed analytics on FULC stock on TipRanks’ Stock Analysis page.
